Cue Biopharma, Inc. (CUE)
Chart Events
Performance Outlook
| Previous Close | 2.6600 |
| Open | 2.7100 |
| Bid | 2.7000 x 1000 |
| Ask | 2.7300 x 1300 |
| Day's Range | 2.6200 - 2.8450 |
| 52 Week Range | 2.3600 - 18.4200 |
| Volume | |
| Avg. Volume | 480,988 |
| Market Cap | 96.036M |
| Beta (5Y Monthly) | 1.74 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.4420 |
| Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CUE
Related Research
- Cue Biopharma, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic Moatlast yearMorningstar
- Simply Wall St.
Shareholders in Cue Biopharma (NASDAQ:CUE) are in the red if they invested a year ago
It's not a secret that every investor will make bad investments, from time to time. But it would be foolish to simply...
- GlobeNewswire
Cue Biopharma to Present at the JMP Securities Life Sciences Conference
BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that it will take part in a fireside chat at the JMP Securities Life Sciences Conference being held June 15–16, 2022. During the fireside chat, Cue Biopharma will provide an overview highlighting its ongoing clinical trials and
- Simply Wall St.
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
